The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Stage

Acquired | Acquired

About Europharma

Europharma is a medical training firm that specializes in strategic consulting, pedagogy, science, health and technology, and creates educational material, medical training content and training programs.

Europharma Headquarter Location

Paris,

France

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Europharma News

Pfizer Taps Brazil Producer to Expand Vaccines in Latin America

Aug 26, 2021

August 26, 2021 - Advertisement - (Businesshala) — Pfizer Inc. and BioNTech SE announced an agreement with a Brazilian manufacturer to produce 100 million doses of their COVID-19 vaccine annually for Latin America. Under the terms announced on Thursday, Brazilian pharmaceutical company Europharma Laboratories SA will carry out a so-called fill-and-finish process in which the vaccine is put into sterile vials. Europharma will start manufacturing the finished dose in 2022 at its facility in So Paulo. In the interim, Pfizer and BioNTech will help facilitate a technology transfer, on-site development and equipment installation. The vaccine material will be shipped from facilities in the US to Brazil, and the finished dose will be distributed exclusively throughout Latin America by Europharma. With the deal, the Pfizer-BioNtech supply chain will expand to more than 20 production facilities across four continents. Vaccine partners said they tap contract manufacturers through “a rigorous selection process” that emphasizes a track record of quality and compliance, a highly trained workforce, available capacity and a prior working relationship. There will now be two facilities in the Southern Hemisphere, using messenger RNA technology built into the Pfizer-BioNTech vaccine. The first came through a similar deal with Biovac Institute, a company partially owned by the South African government. Pfizer signs deal to produce 100 million vaccine doses for Africa The deals follow criticism about unequal access to vaccines around the world. A lack of shots in some countries has hindered efforts to slow the pandemic, particularly as the more-contagious delta variant spreads. The highest-income countries and regions are getting immunized 20 times faster than the lowest-income countries, leaving many still vulnerable to infection. Across Central America and the Caribbean, COVID cases are currently on the rise. Meanwhile, South America continues to face a high number of infections, even as the number of hospitalizations has plummeted. lack of facilities The World Health Organization has suggested that inadequate manufacturing infrastructure is only part of the problem. Most of the Covid-19 vaccine production facilities are concentrated in the US, Europe and Asia. Global health experts from the WHO and beyond have called on the Pfizer-BioNTech partnership and its counterparts to help turn the tide. The Europharma partnership will help provide fair and equitable access to vaccines, Pfizer Chief Executive Officer Albert Boerla said in a statement. He added that the company will continue to explore similar opportunities. To date, Pfizer and BioNTech have shipped more than 1.3 billion doses to more than 120 countries and territories. The companies have partnered with Covax, a global program to equitably distribute vaccines, and is supplying the US government with 500 million doses that it will donate and distribute internationally. build out production Established in 1972, Europharma has manufacturing plants throughout Latin America. The company produces brand-name prescription and generic drugs, over-the-counter medicines, veterinary treatments and hospital products. It has partnered with Pfizer in the past on cardiovascular-focused work. As Europharma opens its facility to fill and dispense the Pfizer-BioNTech COVID Shot, WHO and its Pan American Health Organization unit are simultaneously starting their program to bring mRNA technology to the field. According to Carissa Etienne, director of the Pan American Health Organization, more than 30 public and private companies have expressed interest in participating in the WHO’s mRNA technology transfer program to benefit production in Latin America and the Caribbean. The group will host a series of meetings to promote coordination across countries and to enlist partners. “For regional production to be sustainable, production cannot be concentrated in one place,” she said. ©2011 Businesshala LP

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.